Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibition. - Wilkinson S; Ku AT; Lis RT; King IM; Low D; Trostel SY; Bright JR; Terrigino NT; Baj A; Summerbell ER; Heyward KE; Kartal S; et al. (The Journal of clinical investigation, 2025)